Background: People from British South Asian communities have an increased risk of mortality from coronary heart disease (CHD). Doxazosin, a selective α1-adrenergic blocker, in addition to lowering blood pressure, has been shown to have positive effects on glucose metabolism and lipid profiles in patients with hypertension. Aim: We studied doxazosin (1-8 mg) and bendrofluazide (2.5 mg) in patients of British South Asian origin with existing mild to moderate hypertension (doxazosin n = 78; bendrofluazide n = 82), to compare their effects on glucose and lipid metabolism in this group. Design of Study: A 34-week randomised, double-blind, parallel-group, multicentre study. Setting: Primary care in the UK. Method: All doxazosin patients started with an initial dose of 1 mg once daily, titrated to a maximum 8 mg once daily if diastolic blood pressure was >90 mmHg or was not
